We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Shield Therapeutics Plc | LSE:STX | London | Ordinary Share | GB00BYV81293 | ORD 1.5P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | |
|---|---|---|---|---|---|
| 0.00 | 0.00% | 2.525 | 2.45 | 2.60 |
| High Price | Low Price | Open Price | Shares Traded | Last Trade |
|---|---|---|---|---|
| 2.525 | 2.525 | 2.525 | 360,214 | 08:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 32.18M | -27.18M | -0.0261 | -0.97 | 26.3M |
| Date | Time | Source | Headline |
|---|---|---|---|
| 22/5/2025 | 17:06 | UK RNS | Shield Therapeutics PLC Result of AGM |
| 24/4/2025 | 07:49 | ALNC |  *Shield Therapeutics expects "significant growth" in 2025 |
| 24/4/2025 | 07:06 | UK RNS | Shield Therapeutics PLC Audited results for the year ended 31 Dec 2024 |
| 22/4/2025 | 11:02 | ALNC | Shield Therapeutics inks licencing agreement for iron deficiency drug |
| 22/4/2025 | 07:01 | UK RNS | Shield Therapeutics PLC Licence Agreement in Japan for ACCRUFeR® |
| 17/4/2025 | 21:57 | ALNC | TRADING UPDATES: BP Marsh's new buyback; Iofina lowers production view |
| 17/4/2025 | 11:23 | UK RNS | Shield Therapeutics PLC Q1 2025 Trading Update |
| 11/3/2025 | 07:00 | UK RNS | Shield Therapeutics PLC ACCRUFeR® launched in Canada |
| 13/2/2025 | 16:15 | UK RNS | Shield Therapeutics PLC PDMR Transaction Notification |
| 13/2/2025 | 07:00 | UK RNS | Shield Therapeutics PLC Grant of Share Options |
1 Year Shield Therapeutics Chart |
Intraday Shield Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
